9999999997-17-008524.txt : 20170912
9999999997-17-008524.hdr.sgml : 20170912
20170907142950
ACCESSION NUMBER: 9999999997-17-008524
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20170912
DATE AS OF CHANGE: 20170907
ACTION DATE: 20170912
RECEIVED DATE: 20170907
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 171073628
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S
M=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HR
M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T
M:" V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G (.-094P C$+ P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@
M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;," P(#8Q,B W.3)=
M+TUE9&EA0F]X6S @," V,3(@-SDR72]087)E;G0@." P(%(O4F5S;W5R8V5S
M(#$V(# @4B]2;W1A=&4@,"]4>7!E+U!A9V4^/@UE;F1O8FH-,3,@,"!O8FH-
M/#PO1FEL=&5R+T9L871E1&5C;V1E+T9II))M:]LP$,>_RKW<7F1Z\(-L*(&D
M;;K!DH7:K(.0%YJC)08_!%MEZ;>?3G(D/6=PN2JI/>3JGV[*S-5*4ABAFYE/*M\?--9)R9URTH2SD"P*N6_!\VV%\WE]VDR"
M((*)1X7ICYK&*0^W5EW(,B]>/J1YJ5I8J=_P6)>R^FBUE2P5L8H1K'^=3.9U
ML5NF5D]THW1V(*NZ*65A74^N)&$J^J)ED6>S:E\HH"31JOQN_G/H^L-8++G)
MC[INR(]!*[;1N6P5QKR5_K[*ZEU>[U!-N#Q419\:'RD
MK[*+8$R0Y/FGQH+2YEG9ROKRS-4[?6@W/*" (Z#.#@=JGN>!B\&(O\WQ;C@$
MY]T79Q@*"!D#(2([O2BV4>B/?=_%B:@_&02AU=PMM+?G,O.M\PAHR/6+@.YP9Q#:QGJ:AE2AS2/
MJSYGYP/-TN[6AL,_ @P 95J'KPT*96YDQLUYL'#16@ *;HI E.F:A2%Y*:C9_
MW^%%LI,F 0K40612(@_GG#DS\J>K+8.'=G*133YEF0<,LOV$>>#B'WZE+L1N
M0I, LL>)"P_XGQ7J\C0AX&1_35@",T99"-FEO9/]:@F,NBY+U78[
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M&*F@D]P,NT)5FG8E1=,!_%@;*F6$Q]R4W3%.J
MDC-2C4S$6C4+'T.;]0]]VX)L2I@YS,6T& _O7:\?AK2&]+KG(6SP.,3#'DKV!$@:D19$\8@NA.^3Z9N<@F4C)(%HMMNIT ^&([%_*$8_^KP2>\%;R%M0>;2G)>->0;-?@C4P(Z!8@-30&K9
MX)YYT4TAA#NZI0L*8>C=D]V]V>JD2_%WV(H',^&>,K<=](J%#QQT\D[CB?&-"&B/CE(@[ULU6S,6JPEK)M..?'8[[ >JV";*M@W
M5=4\G16VAGZK3_*A7IY$58$*=\?1KQ77WL70%9R.#M_1\2FZ$U%FHC,4\623
MS$XHO5+"E2D9@2.7HBE;:(^\4)XJ/P^A:=QW6S@6U%B9V&J#=&BA,)0Z.+K8
ML"[Q!8'N@9JZE#LE*S=3;5 SK1Z!*#3P0>ZUV5S"Z"S];7DC>Y?)9OXT_ZOG_RV"93?X18 ""U-%H#0IE;F1S
M=')E86T-96YD;V)J#3$@,"!O8FH-/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I
M7!E+T]B:E-T;3X^R (L'Z+G9V $& (V%"#<-"F5N9'-T
M7!E+UA-
M3"]4>7!E+TUE=&%D871A/CYS=')E86T-"CP_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#4N-BUC,#$U(#@T+C$U.3@Q,"P@,C Q-B\P.2\Q,"TP,CHT,3HS," @
M(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z6YT87@M;G,C(CX*(" @(" @/')D9CI$
M97-C&UL;G,Z>&UP
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X
M;6QN&UL;G,Z>&UP34T](FAT=' Z+R]N&%P+S$N,"]M;2\B/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/E!38W)I<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7 Z0W)E871O&UP34TZ26YS=&%N8V5)1#YU=6ED.C1D
M.39C9C=E+3,R,# M-#%B9BUB9F$T+3@V9#EB,S&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#POJ'
M5!:DZ@?(V]"L(P$(!?Y3:3P22-C461@MA5
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M0D(U-C=".30Q,44S0D,T-4(P1C